The present invention relates to the use of the compound of formula (I) or the pharmaceutically acceptable salts and/or solvates thereof in the treatment of SSTR3 expressing tumors, selected from non-functioning pituitary adenomas (NFPAs) or other neuroendocrine-related malignancies, selected from pancreatic tumors, pheochromocytomas, paragangliomas, lung carcinoids or breast cancer. More specifically, the present invention provides to the use of pharmaceutical compositions comprising the compound of formula (I) or the pharmaceutically acceptable salts and/or solvates thereof and at least one physiologically acceptable excipient in the treatment of a patient affected by SSTR3 expressing tumors, selected from non-functioning pituitary adenomas (NFPAs) or other neuroendocrine-related malignancies, selected from pancreatic tumors, pheochromocytomas, paragangliomas, lung carcinoids or breast cancer.
The present invention relates a method based on mRNA biomarkers that can be used to define the efficacious dose and/or the biological activity of inhibitors of histone deacetylase 6 (HDAC6), such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl) benzamide, during the clinical treatment of patients affected by cancer. More in particular, the invention refers to the analysis of the gene expression's variation of specific biomarkers in human monocytes, as “gene expression signatures”, in a method to evaluate the clinical efficacy of HDAC6 inhibitors, such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical compositions; pharmaceutical preparations; pharmaceutical preparations for rare diseases; Diagnostic preparations and materials, for medical and veterinary purposes; Dietetic substances adapted for medical use; Dietetic foods adapted for medical purposes; Dietary supplements for human beings. Marketing studies; business investigations; organisation of exhibitions for commercial or advertising purposes; publication of publicity texts; market research; business research; public relations; provision of business statistical information. Science and technology services; Technical research; Scientific services and design relating thereto; Technological services and design relating thereto; Scientific research; Industrial analysis and research services; Technological consultancy; Medical research; Research and development services in the field of chemistry; Pharmaceutical research services; Development of pharmaceutical preparations and medicines; Medical and pharmacological research services; Research and development in the field of biotechnology; Pharmaceutical product evaluation. Health counselling; pharmacy advice; professional consultancy relating to health; professional consultancy relating to health care; providing medical information; providing medical information in the healthcare sector; providing information relating to medical services; providing news and information in the field of medicine; providing health information; medical information; medical equipment rental; rental of equipment for medical purposes; hiring of medical instruments; medical screening services in the field of asthma; medical services for the treatment of conditions of the human body; medical screening; pharmaceutical services; medical health assessment services.
The present invention relates to a multiple unit oral dosage form comprising a capsule shell, a first plurality of modified release units of doxylamine or a pharmaceutically acceptable salt thereof and a second plurality of modified release units of pyridoxine or a pharmaceutically acceptable salt thereof, characterized in that said capsule shell does not contain titanium dioxide. It also relates to multiple unit oral dosage form wherein the capsule shell comprises at least one capsule shell material, preferably at least one capsule shell material and at least one organic colourant.
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Management of business projects, namely management of
clinical trial projects, recruitment and selection of
personnel and experts for clinical trials, business
management of clinical trials, arranging service contracts
for others; records management services, namely indexing of
documents for third parties, especially coordination and
control of electronic and paper document flow; data
management services to be used in the following fields:
pharmaceutical drug development namely preparation of case
report forms (CRFs); collection and compilation of data into
a central storage in the following fields: clinical trials;
compilation and provision of statistical and biostatistical
information; medical coding services for third parties,
namely coding of clinical trial data for the purposes of
medical science and of regulatory reviews and approvals;
compilation of data for the purpose of medical science
research and medical consultation; regulatory document
submission management, namely compiling dossiers in
electronic common technical document or common technical
document formats, annual reports, management of article
submissions. Education; training; organization and execution of
conventions, events, congresses, seminars, conferences,
symposia, exhibitions; publication of texts; on-line
publication of books and specialized magazines; multimedia
publication of magazines, specialized magazines and
newspapers; arranging and organization of meetings,
workshops and events; regulatory document submission
management, namely publishing presentations. Scientific and technological services; scientific services
and research related to the same; scientific services and
design related to the same; platform as a service [PAAS]
comprising software platforms for the transmission of
images, audiovisual content, video content and messages;
scientific research for medical purposes; research services,
design and development of instruments for control and
diagnostics; computer diagnostic services, computer analysis
services; scientific research; electronic data storage;
technical writing, namely medical writing services for the
development of medical protocols, clinical study reports,
researcher pamphlets, safety reports, informed consent
forms, meeting summaries, posters, manuscripts, study
diagrams, manuals, and literature reviews; providing online
non-downloadable software featuring clinical study and
clinical trial management system tools via a website;
electronic storage of files and documents; providing online
non-downloadable software featuring study management files;
programming of software for study management files;
electronic storage services for archiving temporary files
throughout the clinical study lifecycle; scientific
research, namely programming of software for biostatistics,
development of protocols for sample size and statistical
power calculations, randomization plans, statistical
analysis plans, programming of software for validation in a
statistical analysis system, providing online
non-downloadable software enabling interpretation and
reporting of data for clinical trial reports and
publications, product development for others; scientific
research, namely intermediate analysis for early decision
making, providing online non-downloadable software featuring
database and data lists ready for a New Drug Application
(NOA), regulatory submission-compliant data files, study
data tabulation and data on model regulatory submission
standards; medical research and development for new products
for others in the field of medical surveillance and safety
plans, ongoing oversight of patient-level studies and review
of safety data, interpretation of study protocol,
consultation on potential safety and medical issues and 24/7
medical surveillance coverage; drug development; drug
discovery of adverse events from clinical trials,
development of safety update reports and other aggregate
reports, development of management safety plans and medical
surveillance plans; quality testing of clinical trial's
documentation, for example, standard operating procedures
(sops) and work instructions, internal system reviews, site
audits, provider evaluations; medical research in the
following areas: pharmacology namely simulation, dose
selection and optimization, biomarker and endpoint
selection, study design optimization, population
pharmacokinetic and pharmacodynamic modeling, exposure
response modeling; medical research; information related to
scientific and medical research in the area of clinical
trials, namely the design of clinical trials and outcome
measures for studying human diseases, or studying or testing
drugs, devices, or medical treatment methods on humans;
conducting clinical trials for third parties studying human
diseases, or studying or testing drugs, devices, or medical
treatment methods on humans; custom computer programming
related to the following fields: image training and
integration into computer systems of suitability data with
interactive response technology (IRT); design and
development of computer databases for the collection,
storage, management, analysis and validation of data for use
in the medical and pharmaceutical fields; electronic storage
services for archiving presentations. Regulatory compliance consultancy, namely legal assistance
to third parties in drafting and compiling applications for
new drugs, legal services relating to the submission and
life cycle management of clinical trial applications to
competent authorities, to ethics committees and to
regulatory agencies, legal assistance concerning submission
of amendments to applications.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, medical and veterinary preparations; Sanitary preparations for medical purposes; Dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for human beings and animals.
The present invention relates to a combination comprising N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide or a pharmaceutically acceptable salt thereof and at least one CTLA4 checkpoint inhibitor, useful in the immunotherapy of tumors and in the treatment of one or more HDAC6-mediated diseases.
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Productos farmacéuticos, preparaciones para uso médico y veterinario; productos higiénicos y sanitarios para uso médico; alimentos y sustancias dietéticas para uso médico o veterinario, alimentos para bebés; suplementos alimenticios para personas o animales.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary products; hygienic and
sanitary products for medical use; dietetic food and
substances for medical or veterinary use, food for babies;
nutritional supplements for humans and animals.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products for gynecological use,
pharmaceutical products for dermatological use; hygienic and
sanitary products for medical use; cosmetic products for
medical use; dietetic food and substances for medical or
veterinary use, food for babies; nutritional supplements for
humans and animals.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Biochemical and chemical preparations for medical use namely chemical reagents for medical purposes and excipients in liquid formulation for oral administration; Biological preparations for medical use for treating neurological and psychiatric diseases, inflammatory diseases, HIV/AIDS, spinal muscular atrophy, chronic juvenile idiopathic arthritis, polycythemia vera, Di Guglielmo's disease, leukemia, myelomas, myelosclerosis, Duchenne muscular dystrophy, Becker muscular dystrophy and other forms of muscular dystrophy; Pharmaceuticals for the treatment of neuromuscular diseases and disorders; Pharmaceuticals for the treatment of genetic diseases.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Biochemical and chemical preparations for medical use, namely, chemical reagents for medical purposes and excipients in a liquid formulation for oral administration; biological preparations for medical use for the treatment of neurological and psychiatric diseases, inflammatory diseases, HIV/AIDS, spinal muscular atrophy, systemic juvenile idiopathic arthritis, polycythaemia vera, essential thrombocythemia, leukemias, myelomas, myelofibrosis, Duchenne muscular dystrophy, Becker muscular dystrophy and other forms of muscular dystrophy; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders; pharmaceutical products for the treatment of genetic disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Biochemical and chemical preparations for medical use,
namely, chemical reagents for medical purposes and
excipients in a liquid formulation for oral administration;
biological preparations for medical use for the treatment of
neurological and psychiatric diseases, inflammatory
diseases, HIV/AIDS, spinal muscular atrophy, systemic
juvenile idiopathic arthritis, polycythaemia vera, essential
thrombocythemia, leukemias, myelomas, myelofibrosis,
duchenne muscular dystrophy, becker muscular dystrophy and
other forms of muscular dystrophy; pharmaceutical
preparations for the treatment of neuromuscular diseases and
disorders; pharmaceutical products for the treatment of
genetic disorders.
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
(1) Management of business projects, namely management of clinical trial projects, recruitment and selection of personnel and experts for clinical trials, business management of clinical trials, arranging service contracts for others; records management services, namely indexing of documents for third parties, especially coordination and control of electronic and paper document flow; data management services to be used in the following fields: pharmaceutical drug development namely preparation of case report forms (CRFs); collection and compilation of data into a central storage in the following fields: clinical trials; compilation and provision of statistical and biostatistical information; medical coding services for third parties, namely coding of clinical trial data for the purposes of medical science and of regulatory reviews and approvals; compilation of data for the purpose of medical science research and medical consultation; regulatory document submission management, namely compiling dossiers in electronic common technical document or common technical document formats, annual reports, management of article submissions.
(2) Education; training; organization and execution of conventions, events, congresses, seminars, conferences, symposia, exhibitions; publication of texts; on-line publication of books and specialized magazines; multimedia publication of magazines, specialized magazines and newspapers; arranging and organization of meetings, workshops and events; regulatory document submission management, namely publishing presentations.
(3) Scientific and technological services; scientific services and research related to the same; scientific services and design related to the same; platform as a service [PAAS] comprising software platforms for the transmission of images, audiovisual content, video content and messages; scientific research for medical purposes; research services, design and development of instruments for control and diagnostics; computer diagnostic services, computer analysis services; scientific research; electronic data storage; technical writing, namely medical writing services for the development of medical protocols, clinical study reports, researcher pamphlets, safety reports, informed consent forms, meeting summaries, posters, manuscripts, study diagrams, manuals, and literature reviews; providing online non-downloadable software featuring clinical study and clinical trial management system tools via a website; electronic storage of files and documents; providing online non-downloadable software featuring study management files; programming of software for study management files; electronic storage services for archiving temporary files throughout the clinical study lifecycle; scientific research, namely programming of software for biostatistics, development of protocols for sample size and statistical power calculations, randomization plans, statistical analysis plans, programming of software for validation in a statistical analysis system, providing online non-downloadable software enabling interpretation and reporting of data for clinical trial reports and publications, product development for others; scientific research, namely intermediate analysis for early decision making, providing online non-downloadable software featuring database and data lists ready for a New Drug Application (NOA), regulatory submission-compliant data files, study data tabulation and data on model regulatory submission standards; medical research and development for new products for others in the field of medical surveillance and safety plans, ongoing oversight of patient-level studies and review of safety data, interpretation of study protocol, consultation on potential safety and medical issues and 24/7 medical surveillance coverage; drug development; drug discovery of adverse events from clinical trials, development of safety update reports and other aggregate reports, development of management safety plans and medical surveillance plans; quality testing of clinical trial's documentation, for example, standard operating procedures (sops) and work instructions, internal system reviews, site audits, provider evaluations; medical research in the following areas: pharmacology namely simulation, dose selection and optimization, biomarker and endpoint selection, study design optimization, population pharmacokinetic and pharmacodynamic modeling, exposure response modeling; medical research; information related to scientific and medical research in the area of clinical trials, namely the design of clinical trials and outcome measures for studying human diseases, or studying or testing drugs, devices, or medical treatment methods on humans; conducting clinical trials for third parties studying human diseases, or studying or testing drugs, devices, or medical treatment methods on humans; custom computer programming related to the following fields: image training and integration into computer systems of suitability data with interactive response technology (IRT); design and development of computer databases for the collection, storage, management, analysis and validation of data for use in the medical and pharmaceutical fields; electronic storage services for archiving presentations.
(4) Regulatory compliance consultancy, namely legal assistance to third parties in drafting and compiling applications for new drugs, legal services relating to the submission and life cycle management of clinical trial applications to competent authorities, to ethics committees and to regulatory agencies, legal assistance concerning submission of amendments to applications.
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Management of business projects, namely management of clinical trial projects in the nature of providing information management services; recruitment and selection of personnel and experts for clinical trials; business management of clinical trials; outsourcing services in the nature of arranging service contracts for others in the field of pharmaceutical development and clinical research; records management services, namely indexing of documents for third parties, especially coordination and control of electronic and paper document flow; database management services in the field of pharmaceutical product development, namely, preparation of case report forms (CRFs); collection and compilation of data into a central storage in the field of clinical trials; compilation and provision of statistical and biostatistical information in the nature of statistical analysis and reporting services for business purposes; medical coding services for third parties, namely coding of clinical trial data for the purposes of medical science and of regulatory reviews and approvals in the nature of compilation and systemization of information into computer databases; compilation of data into computer databases for the purpose of medical science research and medical consultation; regulatory document submission management, namely compiling dossiers in electronic common technical document formats, annual reports, management of article submissions in the nature of records management services, namely document indexing for others. Education services, namely conducting seminars, conferences, workshops, and training sessions in the field of clinical trial management, pharmaceutical development, and regulatory compliance; training services in the field of clinical trial coordination, biostatistics, and data management; organization and execution of conventions, events, congresses, seminars, conferences, symposia, and exhibitions in the field of pharmaceutical and medical research; publication of texts, other than publicity texts; on-line publication of books and specialized magazines; multimedia publication of magazines, specialized magazines and newspapers; arranging and organization of meetings in the nature of seminars, workshops and social entertainment events, namely networking events in the field of pharmaceutical drug development and clinical research; regulatory document submission management, namely publishing presentations as printed matter. Scientific and technological services namely scientific research, analysis, testing, and data computer modeling services in the field of pharmaceutical development, clinical trials, and medical technology; scientific services and scientific research, namely conducting scientific pharmaceutical product feasibility studies and product designing medical devices and instruments for clinical trials; scientific services and product design, namely conducting scientific pharmaceutical product feasibility studies and designing medical devices and instruments for clinical trials; platform as a service (PAAS) comprising software platforms for the transmission of images, audiovisual content, video content and messages; scientific research for medical purposes; product research services, design and development of instruments for control and diagnostics; computer diagnostic services, computer system analysis services; scientific research; electronic data storage; technical writing, namely medical writing services for clinical protocols, study reports, and regulatory dossiers; providing online non-downloadable software featuring clinical study and clinical trial management system tools via a website; electronic storage of files and documents; providing online non-downloadable software providing access to study management files; programming of software for study management files and electronic storage services for archiving temporary files throughout the clinical study lifecycle; scientific research, namely programming of software for biostatistics, development of protocols for sample size and statistical power calculations, randomization plans, and statistical analysis plans; providing online non-downloadable software enabling interpretation and reporting of data for clinical trial reports and publications; product development for others; scientific research, namely intermediate analysis for early decision-making in clinical trials; providing online non-downloadable software for providing access to databases and data lists ready for a New Drug Application (NDA), regulatory submission-compliant data files, study data tabulation, and data on model regulatory submission standards; medical research and development for new products for others in the field of medical surveillance and safety plans; pharmaceutical drug development services; drug discovery services of adverse events from clinical trials; pharmaceutical drug development services, namely development of safety update reports, management safety plans, and medical surveillance plans; product quality testing of clinical trial's documentation, for example, standard operating procedures (SOPs) and work instructions, internal system reviews, site audits, provider evaluations; medical research in the field of pharmacology, namely study design optimization, and modeling of pharmacokinetic population and pharmacodynamic interactions; Information related to scientific and medical research in the area of clinical trials, namely the design of clinical trials and outcome measures for studying human diseases, or studying or testing drugs, devices, or medical treatment methods on humans; Custom computer programming in the field of image training and integration into computer systems of suitability data with interactive response technology (IRT); Product design and development of computer databases for the collection, storage, management, analysis, and validation of data for use in the medical and pharmaceutical fields; Electronic data storage services for archiving presentations. Regulatory compliance consultancy, namely legal assistance to third parties in drafting and compiling applications for new drugs; legal services relating to the submission and lifecycle management of clinical trial applications to competent authorities, ethics committees, and regulatory agencies; legal assistance concerning the submission of amendments to applications for regulatory approval.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Biochemical and chemical preparations for medical use,
namely, chemical reagents for medical purposes and
excipients in a liquid formulation for oral administration;
biological preparations for medical use for the treatment of
neurological and psychiatric diseases, inflammatory
diseases, HIV/AIDS, spinal muscular atrophy, systemic
juvenile idiopathic arthritis, polycythaemia vera, essential
thrombocythemia, leukemias, myelomas, myelofibrosis,
Duchenne muscular dystrophy, Becker muscular dystrophy and
other forms of muscular dystrophy; pharmaceutical
preparations for the treatment of neuromuscular diseases and
disorders; pharmaceutical products for the treatment of
genetic disorders.
21.
DIFLUORO- AND TRIFLUORO-ACETYL HYDRAZIDES AS SELECTIVE HDAC6 INHIBITORS
The present invention relates to acylhydrazides obtained in situ by enzymatic hydrolysis of the parent prodrug 2-(difluoromethyl)- or 2-(trifluoromethyl)-1,3,4- oxadiazole, in histone deacetylase 6 (HDAC6).
C07D 249/06 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Business project management, That is, project management of clinical studies, recruitment and selection of clinical study sites and investigators, management of clinical study sites and clinical monitoring, managing relationships between vendors and subcontractors, organization and planning of meetings, workshops and events; Records management services, namely, document indexing for others, In particular bathtubs, coordinating and controlling flow of electronic and paper documents; Data management services for use in the following fields: pharmaceuticals drug development, That is, preparation of Case Report Forms (CRFs), Collection and compilation of information into computer databases in the following fields: Clinical studies; Compilation and provision of statistical and biostatistical information. Teaching; Training; Arranging and conducting of conventions, events, congresses, seminars, conferences, symposia, exhibitions; Publication of texts; Online publication of specialist magazines and books; Multimedia publishing of magazines, journals and newspapers. Science and technology services; Scientific services and research relating thereto; Scientific services and design relating thereto; Platform as a service [PaaS] featuring software platforms for transmission of images, audio-visual content, video content and messages; Scientific investigation for medical purposes; Research, design and development of monitoring and diagnostic tools; Computer analysis, prediction and diagnostics; Scientific research; Electronic data storage; Technical writing, namely, medical writing services for developing medical protocols, clinical study reports, investigator brochures, safety reports, informed consent forms, meeting abstracts, posters, manuscripts, study charts, manuals and literature reviews; Providing an Internet website portal featuring clinical study and clinical trial management system tools; Electronic storage of files and documents, trial management files (TMF), TMF setup, archiving and management of TMP files through lifecycle of clinical study; Research services, namely, biostatistics and statistical programming, protocol development of sample size and power calculations, randomization schedules, statistical analysis plans, statistical programming and validation in statistical analysis system, statistical analyses, interpretation and reporting of data for clinical trial reports and publications, statistical and strategic consulting for product development; Research services, Namely, interim analysis for early decision-making, database integration, New Drug Application (NDA) ready data listings, regulatory submission compliant datasets, thought leadership and operational experience with study data tabulation model and analysis data model regulatory submission standards; Research services, Namely, integrated safety and efficacy summaries, adaptive design consulting and simulation support, translational research support data monitoring board management and support; Medical research, Namely, medical surveillance and search site surveillance in the field of medical revision of clinical study materials, preparation of medical surveillance and safety plans, continuous monitoring of patient studies and revision of safety data; Medical research, Namely, support in subject suitability for researchers, medical support to sites and study groups for the interpretation of study protocols, consultancy on potential security problems and medical problems and 24/7 medical surveillance; Pharmaceutical drug development services; drug safety, In particular computer-assisted, processing adverse events from clinical trials, preparing Development Safety Update Reports (DSURs) and other aggregate reports, performing signal detection and benefit-risk assessments, preparing safety management plans and preparing medical monitoring plans; Providing quality assurance services in the following fields: Clinical trials, namely, quality assistance documentation, For example, Standard Operating Procedures (SOPs) and work instructions, internal system reviews, site audits, vendor assessments; Medical research in the following fields: Pharmacology, namely, dose simulation, selection and optimization, selection of biomarkers and endpoints, optimization of trial design, population pharmacokinetic and pharmacodynamic modeling, exposure response modeling; Medical research; Providing medical and scientific research information in the field of clinical trials, namely, the design of clinical trials and outcome measures for studying human diseases, or for studying or testing drugs, devices or methods of medical treatment on humans; Conducting clinical trials for others which study human diseases, or study or test drugs, devices or methods of medical treatment on humans; Custom computer programming services, in relation to the following fields: imaging adjudication and computer systems integration of eligibility data with Interactive Response Technology (IRT); Computer database design and implementation for data collection, data storage, data management, data analysis, and data validation, for use in the following fields: medical field and Pharmaceutical field; Compilation of data For research purposes, in relation to the following fields: medical science and Provision of technical advice and consultation services; Medical coding for others, namely, coding of clinical trial data for purposes of medical science and regulatory review and approvals. Regulatory submission management, namely, assisting others in preparing and filing applications for new drugs with governmental regulatory bodies, submission planning and life cycle management of clinical trial applications to Competent Authorities, Ethics Committees and Regulatory Agencies, pre-approval submissions, submission of supplements, amendments and variations applications; Regulatory submission management, namely, submission publishing and dossier compilation in electronic common technical document or common technical document formats, annual reports, paper submissions management and submission archival.
23.
1,3,4-OXADIAZOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS
The present invention relates to selective oxadiazole-based inhibitors of histone deacetylase 6 (HDAC6) and uses thereof in treating various diseases and disorders.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Biochemical and chemical preparations for medical use, namely, chemical reagents for medical purposes and excipients in a liquid formulation for oral administration; biological preparations for medical use for the treatment of neurological and psychiatric diseases, inflammatory diseases, HIV/AIDS, spinal muscular atrophy, systemic juvenile idiopathic arthritis, polycythaemia vera, essential thrombocythemia, leukemias, myelomas, myelofibrosis, Duchenne muscular dystrophy, Becker muscular dystrophy and other forms of muscular dystrophy; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders; pharmaceutical products for the treatment of genetic disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Biochemical and chemical preparations for medical use, namely, chemical reagents for medical purposes and excipients in a liquid formulation for oral administration; biological preparations for medical use for the treatment of neurological and psychiatric diseases, inflammatory diseases, HIV/AIDS, spinal muscular atrophy, systemic juvenile idiopathic arthritis, polycythaemia vera, essential thrombocythemia, leukemias, myelomas, myelofibrosis, duchenne muscular dystrophy, becker muscular dystrophy and other forms of muscular dystrophy; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders; pharmaceutical products for the treatment of genetic disorders.
26.
Process for preparing {6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate having high purity
A process for obtaining {{6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate and/or pharmaceutically acceptable salts thereof having high purity is described. This process allows to obtain a product having an amount of any single unknown impurity equal to or less than 0.10%, as well as a product having a purity greater than 99.5%, preferably equal to or greater than 99.6%.
A process for obtaining {{6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate and/or pharmaceutically acceptable salts thereof having high purity is described. This process allows to obtain a product having an amount of any single unknown impurity equal to or less than 0.10%, as well as a product having a purity greater than 99.5%, preferably equal to or greater than 99.6%.
An HPLC method for determining the purity of the product and possible impurities thereof is also described.
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
C07C 269/06 - Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
B01J 20/286 - Phases chemically bonded to a substrate, e.g. to silica or to polymers
C07C 269/08 - SeparationPurificationStabilisationUse of additives
The present invention relates to novel selective oxadiazole-based inhibitors of histone deacetylase 6 (HDAC6) bearing a pentaheterocyclic scaffold and pharmaceutical compositions thereof.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
28.
USE OF SOMATOSTATIN AGONIST IN THE TREATMENT OF SSTR3 EXPRESSING TUMORS
The present invention relates to the use of the compound of formula (I) or the pharmaceutically acceptable salts and/or solvates thereof in the treatment of SSTR3 expressing tumors, selected from non-functioning pituitary adenomas (NFPAs) or other neuroendocrine-related malignancies, selected from pancreatic tumors, pheochromocytomas, paragangliomas, lung carcinoids or breast cancer.More specifically, the present invention provides to the use of pharmaceutical compositions comprising the compound of formula (I) or the pharmaceutically acceptable salts and/or solvates thereof and at least one physiologically acceptable excipient in the treatment of a patient affected by SSTR3 expressing tumors, selected from non-functioning pituitary adenomas (NFPAs) or other neuroendocrine-related malignancies, selected from pancreatic tumors, pheochromocytomas, paragangliomas, lung carcinoids or breast cancer.
The present invention relates a method based on mRNA biomarkers that can be used to define the efficacious dose and/or the biological activity of inhibitors of histone deacetylase 6 (HDAC6), such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1 H-tetrazol-1 -yl)methyl) benzamide, during the clinical treatment of patients affected by cancer. More in particular, the invention refers to the analysis of the gene expression's variation of specific biomarkers in human monocytes, as "gene expression signatures", in a method to evaluate the clinical efficacy of HDAC6 inhibitors, such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1 H-tetrazol-1 -yl)methyl)benzamide.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The present invention relates a method based on mRNA biomarkers that can be used to define the efficacious dose and/or the biological activity of inhibitors of histone deacetylase 6 (HDAC6), such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1 H-tetrazol-1 -yl)methyl) benzamide, during the clinical treatment of patients affected by cancer. More in particular, the invention refers to the analysis of the gene expression's variation of specific biomarkers in human monocytes, as "gene expression signatures", in a method to evaluate the clinical efficacy of HDAC6 inhibitors, such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1 H-tetrazol-1 -yl)methyl)benzamide.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, in particular supplements based on extracts
of hawthorn, lavender and hops for treating and/or
preventing sleep disturbances, including insomnia and
middle-of-the-night insomnia; nutritional supplements;
nutritional supplements; dietetic substances adapted for
medical use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products, preparations for medical use;
hygienic and sanitary products for medical use; dietetic
substances and foods for medical use, food for babies; food
supplements for persons.
35.
A COMBINATION COMPRISING A SPECIFIC HDAC6 INHIBITOR AND AT LEAST ONE CTLA4 CHECKPOINT INHIBITOR
The present invention relates to a combination comprising N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide or a pharmaceutically acceptable salt thereof and at least one CTLA4 checkpoint inhibitor, useful in the immunotherapy of tumors and in the treatment of one or more HDAC6-mediated diseases.
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
36.
A COMBINATION COMPRISING A SPECIFIC HDAC6 INHIBITOR AND AT LEAST ONE CTLA4 CHECKPOINT INHIBITOR
The present invention relates to a combination comprising N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide or a pharmaceutically acceptable salt thereof and at least one CTLA4 checkpoint inhibitor, useful in the immunotherapy of tumors and in the treatment of one or more HDAC6-mediated diseases.
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A process for obtaining {{6-[(diethylamino)methyl]naphthalen-2-yl}methyl[4-(hydroxycarbamoyl)phenyl]carbamate and/or pharmaceutically acceptable salts thereof having high purity is described. This process allows to obtain a product having an amount of any single unknown impurity equal to or less than 0.10%, as well as a product having a purity greater than 99.5%, preferably equal to or greater than 99.6%.
An HPLC method for determining the purity of the product and possible impurities thereof is also described.
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
B01J 20/286 - Phases chemically bonded to a substrate, e.g. to silica or to polymers
C07C 269/06 - Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
C07C 269/08 - SeparationPurificationStabilisationUse of additives
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Food supplements; Nutraceuticals; Probiotic supplements; Functional food for improvement of basal glycaemia and insulin resistance in patients prone to developing type 2 diabetes; Banaba-based supplements, linked to chromium picolinate.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Food supplements; Nutraceuticals; Probiotic supplements; Functional food for improvement of basal glycaemia and insulin resistance in patients prone to developing type 2 diabetes; Banaba-based supplements, linked to chromium picolinate.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Food supplements; Nutraceuticals; Probiotic supplements; Functional food for improvement of basal glycaemia and insulin resistance in patients prone to developing type 2 diabetes; Banaba-based supplements, linked to chromium picolinate.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Biochemical and chemical preparations for medical use, namely, chemical reagents for medical purposes and excipients in a liquid formulation for oral administration; biological preparations for medical use for the treatment of neurological and psychiatric diseases, inflammatory diseases, HIV/AIDS, spinal muscular atrophy, systemic juvenile idiopathic arthritis, polycythaemia vera, essential thrombocythemia, leukemias, myelomas, myelofibrosis, Duchenne muscular dystrophy, Becker muscular dystrophy and other forms of muscular dystrophy; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders; pharmaceutical products for the treatment of genetic disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; chemical and biochemical products for medical purposes; Biological preparations for medical use; Pharmaceuticals for the treatment of neuromuscular diseases and disorders; Pharmaceuticals for the treatment of genetic diseases.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; chemical and biochemical products for medical purposes; Biological preparations for medical use; Pharmaceuticals for the treatment of neuromuscular diseases and disorders; Pharmaceuticals for the treatment of genetic diseases.
Compounds of formula (I) as selective inhibitors of histone deacetylase 6 (HDAC6) for use in treating e.g. peripheral neuropathy, graft rejection, GVHD, myositis, diseases associated with abnormal lymphocyte function, multiple myeloma, non-Hodgkin lymphoma, autoimmune diseases, inflammatory diseases, cancer and neurodegenerative pathologies. Preferred compounds are e.g. 2-(4-((5-(benzo[b]thiophen-3-yl)-1H- tetrazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole derivatives and related compounds.
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
C07D 413/08 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
2-(4-((5-(BENZO[B]THIOPHEN-3-YL)-1H-TETRAZOL-1-YL)METHYL)PHENYL)-5-(DIFLUOROMETHYL)-1,3,4-OXADIAZOLE DERIVATIVES AND SIMILAR COMPOUNDS AS SELECTIVE INHIBITORS OF HISTONE DEACETYLASE 6 (HDAC6) FOR USE IN TREATING E.G. PERIPHERAL NEUROPATHY
Compounds of formula (I) as selective inhibitors of histone deacetylase 6 (HDAC6) for use in treating e.g. peripheral neuropathy, graft rejection, GVHD, myositis, diseases associated with abnormal lymphocyte function, multiple myeloma, non-Hodgkin lymphoma, autoimmune diseases, inflammatory diseases, cancer and neurodegenerative pathologies. Preferred compounds are e.g. 2-(4-((5-(benzo[b]thiophen-3-yl)-1H- tetrazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole derivatives and related compounds.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/08 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Pharmaceutical specialities for use in treating mild to moderate dementia caused by Alzheimer's disease; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases, generated by or acting on the central nervous system; Pharmaceutical preparations for the treatment of central nervous system [CNS] diseases.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Pharmaceutical specialities for use in treating mild to moderate dementia caused by Alzheimer's disease; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases, generated by or acting on the central nervous system; Pharmaceutical preparations for the treatment of central nervous system [CNS] diseases.
The present invention relates to novel benzohydroxamic compounds of formula (I) and (II) and pharmaceutically acceptable salts, isomers and prodrugs thereof, exhibiting a high selective inhibitory activity against histone deacetylase 6 (HDAC6) enzyme.
A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61P 25/00 - Drugs for disorders of the nervous system
C07D 271/113 - 1,3,4-OxadiazolesHydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
C07D 285/125 - 1,3,4-ThiadiazolesHydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
52.
USE OF HISTONE DEACETYLASE INHIBITORS FOR THE CARE OF PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE SYNDROMES
Method of treating Philadelphia-negative myeloproliferative syndromes in a patient suffering therefrom by administering to the patient diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, in a daily dosage amount of from 50 to 100 mg per patient.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical drugs for alleviating symptoms of intermittent claudication in peripheral vascular disease; Pharmaceutical drugs for preventing re-occlusions after revascularisation procedures; Antithrombotics, antiplatelet drugs.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Biochemical and chemical preparations for medical use, namely, chemical reagents for medical purposes and excipients in a liquid formulation for oral administration; biological preparations for medical use for the treatment of neurological and psychiatric diseases, inflammatory diseases, HIV/AIDS, spinal muscular atrophy, systemic juvenile idiopathic arthritis, polycythaemia vera, essential thrombocythemia, leukemias, myelomas, myelofibrosis, Duchenne muscular dystrophy, Becker muscular dystrophy and other forms of muscular dystrophy; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders; pharmaceutical products for the treatment of genetic disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Biochemical and chemical preparations for medical use, namely, chemical reagents for medical purposes and excipients in a liquid formulation for oral administration; biological preparations for medical use for the treatment of neurological and psychiatric diseases, cancer, inflammatory diseases, HIV/AIDS, spinal muscular atrophy, systemic juvenile idiopathic arthritis, polycythaemia vera, essential thrombocythemia, leukemias, myelomas, myelofibrosis, Duchenne muscular dystrophy, Becker muscular dystrophy and other forms of muscular dystrophy; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders; pharmaceutical products for the treatment of genetic disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical specialities; chemical and biochemical products for medical purposes; Biological preparations for medical use; Pharmaceuticals for the treatment of neuromuscular diseases and disorders; Pharmaceuticals for the treatment of genetic diseases.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; chemical and biochemical products for medical purposes; Biological preparations for medical use; Pharmaceuticals for the treatment of neuromuscular diseases and disorders; Pharmaceuticals for the treatment of genetic diseases.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical specialities except antimycotics; chemical and biochemical products for medical purposes except antimycotics; Biological preparations for medical use except antimycotics; Pharmaceuticals for the treatment of neuromuscular diseases and disorders; Pharmaceuticals for the treatment of genetic diseases.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical specialities for use in treating mild to moderate dementia caused by Alzheimer's disease; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases, generated by or acting on the central nervous system.
60.
PROCESS FOR PREPARING {6-[(DIETHYLAMINO)METHYL]NAPHTHALEN-2-YL}METHYL [4-(HYDROXYCARBAMOYL)PHENYL]CARBAMATE HAVING HIGH PURITY
C07C 269/06 - Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
C07C 269/08 - SeparationPurificationStabilisationUse of additives
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
61.
PROCESS FOR PREPARING {6-[(DIETHYLAMINO)METHYL]NAPHTHALEN-2-YL}METHYL [4-(HYDROXYCARBAMOYL)PHENYL]CARBAMATE HAVING HIGH PURITY
A process for obtaining { {6-[(diethylamino)methyljnaphthalen-2-yl}methyl [4- (hydroxycarbamoyl)phenyl]carbamate and/or pharmaceutically acceptable salts thereof having high purity is described. This process allows to obtain a product having an amount of any single unknown impurity equal to or less than 0.10%, as well as a product having a purity greater than 99.5%, preferably equal to or greater than 99.6%. An HPLC method for determining the purity of the product and possible impurities thereof is also described.
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
62.
PROCESS FOR PREPARING {6-[(DIETHYLAMINO)METHYL]NAPHTHALEN-2-YL}METHYL [4-(HYDROXYCARBAMOYL)PHENYL]CARBAMATE HAVING HIGH PURITY
A process for obtaining {{6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4- (hydroxycarbamoyl)phenyl]carbamate and/or pharmaceutically acceptable salts thereof having high purity is described. This process allows to obtain a product having an amount of any single unknown impurity equal to or less than 0.10%, as well as a product having a purity greater than 99.5%, preferably equal to or greater than 99.6%. An HPLC method for determining the purity of the product and possible impurities thereof is also described.
C07C 269/06 - Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
C07C 269/08 - SeparationPurificationStabilisationUse of additives
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations; Sanitary products for medical use; Foodstuffs and dietetic substances for medical or veterinary purposes; Dietetic supplements for human or animal use; Food for babies.
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Medicine; Medicines for human purposes; Chemico-pharmaceutical preparations; Chemico-pharmaceutical preparations; Diagnostic agents for medical use; Diagnostic agents for pharmaceutical use; Medicated food supplements; Medical preparations; Medicinal substances; Medicinal ointments; Hormone preparations for pharmaceutical use; Mixed hormone preparations; Gastrointestinal preparations; anti-emetic products; Anti-emetics; Anti-nauseants; Preparations against morning sickness; Preparations against pregnancy-related illnesses; Preparations against discomfort in pregnancy; Preparations to treat hormone-related illnesses; Preparations to treat anxiety and stress-related illnesses; Preparations to increase physical wellbeing in pregnancy; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Preparations for vein disorders; Anti-thrombosis preparations; Preparations to inhibit blood clotting; Preparations to treat venous thromboembolism; Preparations to prevent venous thromboembolism illnesses; Preparations to treat deep vein thrombosis; Preparations to treat lung embolism; Preparations to prevent blood clotting; Preparations to treat acute coronary syndrome; Pharmaceutical products and preparations to prevent swelling in the legs; Plant extracts for pharmaceutical purposes; Herbal supplements; Pharmaceuticals; Pharmaceutical compositions; Pharmaceutical preparations for human use; Pharmaceutical preparations and substances; Pharmaceutical preparations; Pharmaceutical preparations for use in oncology; Pharmaceuticals for gynaecology; Pharmaceutical preparations for cardiology; Chemical preparations for the diagnosis of pregnancy; Hormones for medical purposes; Hormone suppressing preparations; Pharmaceutical preparations for the prevention of disorders of the endocrine system; Pharmaceutical preparations for the treatment of disorders of the endocrine system; Cardiovascular pharmaceuticals; Gastrointestinal preparations; Pre-filled syringes for medical purposes; Filled syringes for medical purposes [containing pharmaceuticals]; Injectable pharmaceuticals; Injection solutions in a syringe. Preparing audio-visual presentations for use in advertising; audiovisual advertisements; Preparation of advertising material; Information services relating to advertising; Outdoor advertising; Banner advertising; Computerised business promotion; Digital marketing; Analysis of advertising response and market research; Preparation of publicity publications; Web indexing for commercial or advertising purposes; Advertising services provided via the internet; Marketing; Marketing and promotion services; Internet marketing; Search engine marketing services; Trade fairs and exhibitions; Merchandising; Public relations services; Online advertisements; Web site traffic optimization; Search engine optimisation; On-line advertising and marketing services; Planning services for advertising; Press advertising services; Production of advertising matter and commercials; Product marketing; Product demonstrations and product display services; Collection of information relating to advertising; Writing, preparing and publication of texts for advertising purposes; Trade promotional services; Promotional marketing; Sales promotion using audiovisual media; Publicity and sales promotion services; Publication of publicity materials; Distribution of advertising, marketing and promotional material; Advertising; Publicity and sales promotion services; Advertising; Advertising via electronic media and specifically the internet; Advertising in periodicals, brochures and newspapers; Advertising business especially in the field of telematic and telephone networks; Advertising services provided via a data base; Direct marketing; Advertising and marketing; Advertising; Direct mail advertising; Direct mail advertising; Dissemination of advertising matter online; Dissemination of advertisements via the Internet; Dissemination of advertisements; Advertising by mail order; Consultancy and support in the field of advertising; Advice relating to marketing management; Mediation and conclusion of commercial transactions for others; Provision of information concerning commercial sales; Provision of information and advisory services relating to e-commerce; Subscription services; Ordering services; Ordering services for third parties; Wholesale ordering services; Computerized on-line ordering services; Computerised stock ordering; Import-export agency services; Comparison shopping services; Electronic order processing; Providing market information in relation to consumer products; Import-export agency services; Information about sales methods; Commercial administration of the licensing of the goods and services of others; Loyalty, incentive and bonus program services; Providing consumer product advice; Online ordering services; Price comparison services; Telephone order-taking services for others; Telemarketing services; Sales administration; Mediation of agreements regarding the sale and purchase of goods; Intermediary services relating to advertising; Business management; Office functions; Office functions services; Computerised office management; Business management; Business management services relating to electronic commerce; Business administration and management; Business management of wholesale and retail outlets; Business management; Commercial assessment; Organising of business contacts; Collective buying; Negotiation and conclusion of commercial transactions for third parties via telecommunication systems; Commercial intermediation services; Administration of foreign business affairs; Commercial management; Customer relationship management; Balance sheet accounting; Book-keeping and accounting services; Bookkeeping for electronic funds transfer; Book-keeping; Drawing up of statements of accounts; Book-keeping; Administrative data processing; Data processing, systematisation and management; Addressing of envelopes; Clerical services for the taking of sales orders; Business records keeping; Market surveys conducted by telephone; Telephone answering for unavailable subscribers; Word processing and typing services; Word processing; Preparation of mailing lists; Drawing up of business statistical information; Computerized file management; Information services relating to data processing; Business analysis, research and information services; Cost-price analysis; Marketing studies; Computerised inventory control; Acquisition of business information relating to company activities; Computerised data processing; Computerised stock management; Computerised compilation of order lists; Computerised compilation of stock control records; Computerised compilation of customer indexes; Computerized file management; Computerized file management; Collection and systematisation of information into computer databases; Compilation of statistics; Administrative processing of purchase orders; Personnel management and Staff restructuring; Collection of data; Collecting information for business; Collection and systematization of business data; Sales volume tracking for others; Business records management; Telephone switchboard services; Business consultancy and advisory services; Rental of objects in connection with the providing of the aforesaid services, included in this class; Consultancy and information in relation to the aforesaid services, included in this class. Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Consultancy relating to pharmaceutical research and development; Consultancy relating to research and development in the field of therapeutics; Consultancy relating to laboratory testing; Providing information about the results of clinical trials for pharmaceutical products; Pharmaceutical product evaluation; Biological research, clinical research and medical research; Biomedical research services; Scientific and technological services in the field of safety of medicines; Medical research laboratory services; Medical laboratory services; Services for assessing the efficiency of pharmaceuticals; Testing of pharmaceuticals; Conducting early evaluations in the field of new pharmaceuticals; Conducting clinical trials for pharmaceutical products; Clinical research; Development of pharmaceutical preparations and medicines; Pharmaceutical products development; Research and development of vaccines and medicines; Providing information on clinical studies via an interactive website; Providing scientific information in the field of medical disorders and their treatment; Research on the subject of pharmaceuticals; Research on the subject of pharmaceuticals; Clinical research; Clinical trials; Clinical trials; Medical research; Pharmaceutical drug development services; Pharmaceutical research and development; Inspection of pharmaceuticals; Scientific research and development; Advisory services relating to chemical reagents; Advisory services relating to biochemistry; Chemical analysis; Analysis of product development; Analysis of product design; Authentication services; Quality assurance consultancy; Consultancy services relating to quality control; Product quality evaluation; Computer aided scientific testing; Computer aided diagnostic testing services; Computer aided industrial testing; Quality checking and testing; Quality audits; Scientific testing services; Scientific testing services; Development of testing methods; Process monitoring for quality assurance. Therapy; Monitoring of patients; Professional consultancy relating to health; Medical services; Medical and healthcare clinics; Medical services; Medical information services provided via the Internet; Medical counseling relating to stress; Medical consultancy relating to oncology; Medical consultancy relating to cardiology; Medical consultancy relating to gynaecology; Pharmaceutical services; Medical information; Health advice and information services; Provision of information relating to medicine; Medication counseling; Physician services; Medical care; Advisory services relating to medical problems; Providing information to patients in the field of administering medications; Advisory services relating to medical services; Providing news and information in the field of medicine; Medical counseling; Medical consultations; Consultancy and information services relating to medical products; Providing medical support in the monitoring of patients receiving medical treatments; Medical assistance; Medical clinic services; Paramedical services; Services for the preparation of medical reports; Medical screening; Conducting of medical examinations; Physical examination services; Issuing of medical reports; Medical health assessment services; Preparation of reports relating to medical matters; Performing diagnosis of diseases; Medical information; Providing medical information in the healthcare sector; Providing of online information relating to medicines; Providing of information relating to oncology; Providing of information relating to gynaecology; Providing of information relating to cardiology; Medical counseling; Medical evaluation services; Medical diagnostic services; Medical services in the field of oncology; Medical services in the field of gynaecology; Medical services in the field of cardiology; Charitable services, namely providing medical services; Medical assistance; Providing information relating to medical services; Providing information relating to physical examinations; Arranging of medical treatment; Compilation of medical reports; Dispensing of pharmaceuticals; Consultancy and information services provided via the Internet relating to pharmaceutical products; Consultancy and information services relating to pharmaceutical products.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, namely pharmaceuticals containing a
combination of doxylamine and pyridoxine indicated for
managing nausea and vomiting during pregnancy, anti-emetic
pharmaceutical preparations.
68.
Benzo-N-hydroxy amide compounds having antitumor activity
The present invention relates to new benzo-N-hydroxy amide compounds of formula (I) and pharmaceutically acceptable salts, isomers and prodrugs thereof, which show a significant inhibitory activity on the proliferation of tumor cells and specifically of cancer stem cells.
C07D 317/60 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 215/14 - Radicals substituted by oxygen atoms
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 209/18 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07C 259/10 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
C07D 221/04 - Ortho- or peri-condensed ring systems
C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
C07D 317/06 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2 condensed with carbocyclic rings or ring systems
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, namely pharmaceuticals containing a
combination of doxylamine and pyridoxine indicated for
managing nausea and vomiting during pregnancy; antiemetic
pharmaceutical preparations.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products, hygienic and sanitary products for
medical use, dietetic substances and food for medical use,
food for babies, nutritional supplements for human beings.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products; preparations for medical and
veterinary use; hygiene and sanitary products for medical
use; dietetic food and substances for medical or veterinary
use; food for babies; food supplements for humans or
animals; plasters, material for dressings; material for
filling teeth and dental impressions; disinfectants;
products for destroying vermin; fungicides, herbicides.
72.
HC-CDR3-only libraries with reduced combinatorial redundancy and optimized loop length distribution
The present invention provides for a library of vectors comprising human HC-CDR3 regions of varying length, wherein the diversity of said library is focused on the HC-CDR3 region only and diversity has been optimized such that redundancy is reduced for short HC-CDR3 loops and coverage of HC-CDR3 region variants for longer loop lengths has been increased. The library of the present invention is displayed on phage for selection against target antigens.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, In particular supplements based on myo-inositol, folic acid and α-lactalbumin, for use by inositol-resistant PCOS patients, Nutritional supplements; Nutritional supplements; Dietetic substances adapted for medical use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, In particular supplements based on myo-inositol, 1D-chiro-inositol, folic acid and α-lactalbumin, for use by patients who are inositol-resistant for the adjuvant treatment of polycystic ovary syndrome, insulin-resistant conditions, pre-diabetic conditions, type 2 diabetes and gestational diabetes; Nutritional supplements; Nutritional supplements; Dietetic substances adapted for medical use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, Namely pharmaceuticals containing a combination of doxylamine and pyridoxine indicated for managing nausea and vomiting during pregnancy; Anti-emetic pharmaceutical preparations.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, medical preparations; Sanitary products for medical use; all the above only applied for the treatment of schizophrenia, bipolar disorder, major depressive disorder and as a sedative drug.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, Namely pharmaceuticals containing a combination of doxylamine and pyridoxine indicated for managing nausea and vomiting during pregnancy; Anti-emetic pharmaceutical preparations.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, in particular supplements based on extracts of hawthorn, lavender and hops for treating and/or preventing sleep disturbances, including insomnia and middle-of-the-night insomnia; Nutritional supplements; Nutritional supplements; Dietetic substances adapted for medical use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, in particular supplements based on extracts of hawthorn, lavender and hops for treating and/or preventing sleep disturbances, including insomnia and middle-of-the-night insomnia; Nutritional supplements; Nutritional supplements; Dietetic substances adapted for medical use.
85.
Physically and chemically stable oral suspensions of givinostat
Physically and chemically stable oral liquid formulations of Givinostat (Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride) are disclosed, together with methods for the preparation thereof. Such oral formulations are in the form of aqueous suspensions and contain Givinostat and/or pharmaceutically acceptable salts and/or derivatives thereof, at least a wetting agent and/or at least a density-imparting agent. Such formulations are suitable for oral administration for systemic therapeutic action.
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
The present invention relates to novel benzohydroxamic compounds of formula (I) and (II) and pharmaceutically acceptable salts, isomers and prodrugs thereof, exhibiting a high selective inhibitory activity against histone deacetylase 6 (HDAC6) enzyme.
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
C07D 271/113 - 1,3,4-OxadiazolesHydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
The present invention relates to novel benzohydroxamic compounds of formula (I) and (II) and pharmaceutically acceptable salts, isomers and prodrugs thereof, exhibiting a high selective inhibitory activity against histone deacetylase 6 (HDAC6) enzyme.
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 271/113 - 1,3,4-OxadiazolesHydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 25/00 - Drugs for disorders of the nervous system
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products and more precisely supplements for
the treatment of hyperuricaemia; dietary supplements for
medical use; food supplements for medical use; vitamin
preparations in the form of food supplements; drinks based
on dietary supplements; dietary products for medical use.
89.
HC-CDR3-ONLY LIBRARIES WITH REDUCED COMBINATORIAL REDUNDANCY AND OPTIMIZED LOOP LENGTH DISTRIBUTION
The present invention provides for a library of vectors comprising human HC-CDR3 regions of varying length, wherein the diversity of said library is focused on the HC-CDR3 region only and diversity has been optimized such that redundancy is reduced for short HC-CDR3 loops and coverage of HC-CDR3 region variants for longer loop lengths has been increased. The library of the present invention is displayed on phage for selection against target antigens.
C40B 40/08 - Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
C40B 40/10 - Libraries containing peptides or polypeptides, or derivatives thereof
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
The present invention relates to new benzo-N-hydroxy amide compounds of formula (I) and pharmaceutically acceptable salts thereof, which show a significant inhibitory activity on the proliferation of tumor cells and specifically of cancer stem cells.
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/4406 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
C07C 259/10 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
C07D 209/18 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
C07D 317/60 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
92.
BENZO-N-HYDROXY AMIDE COMPOUNDS HAVING ANTITUMOR ACTIVITY
The present invention relates to new benzo-N-hydroxy amide compounds of formula (I) and pharmaceutically acceptable salts thereof, which show a significant inhibitory activity on the proliferation of tumor cells and specifically of cancer stem cells.
C07D 215/14 - Radicals substituted by oxygen atoms
C07C 259/10 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
C07D 317/60 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 209/18 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/4406 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products, preparations for medical and
veterinary use, hygienic and sanitary products for medical
use; dietetic food and substances for medical or veterinary
use, food for babies.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical, veterinary and sanitary products; dietetic
substances for medical use, food for babies; plasters,
material for dressings; material for dental fillings and
dental impressions; disinfectants; products for destroying
vermin; fungicides, herbicides.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary products; sanitary products
for medical purposes; dietetic substances for medical use,
food for babies; plasters, material for dressings; material
for dental fillings and for dental impressions;
disinfectants; products for destroying vermin; fungicides,
herbicides.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products; hygienic and sanitary preparations
for medical use; dietetic food and substances for medical
or veterinary use; food for babies; food supplements for
humans or animals.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products; preparations for medical use;
dietetic food and substances for medical or veterinary use;
food for babies; food supplements for humans or animals.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, medical preparations; Sanitary preparations for medical purposes; Dietetic food and substances adapted for medical use, food for babies; Food supplements for human beings.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Pharmaceutical and veterinary preparations; Sanitary preparations for medical purposes; Dietetic food and substances adapted for medical use, food for babies; Food supplements for human beings.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products; except pharmaceutical products for
skin or hair use; dietetic substances and foodstuffs for
medical use; nutritional supplements for humans.
